{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T18:44:37Z","timestamp":1780512277199,"version":"3.54.1"},"reference-count":47,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T00:00:00Z","timestamp":1276732800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research"],"published-print":{"date-parts":[[2010,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>INTRODUCTION<\/jats:bold>: Ribavirin, with interferons or pegylated interferons, is used to treat chronic hepatitis C. Ribavirin is contraindicated in pregnancy (FDA Pregnancy Category X) and in men whose partners may become pregnant. In 2003, the Ribavirin Pregnancy Registry was established to monitor pregnancy exposures to ribavirin and to evaluate the potential human teratogenicity of prenatal exposure.<jats:bold>METHODS<\/jats:bold>: This voluntary registry enrolls pregnant women who have been exposed to ribavirin during pregnancy or during the six months prior to conception either directly, by taking ribavirin, or indirectly through sexual contact with a man taking ribavirin. Women are followed until delivery; live born infants are followed for one year. The Registry aims to enroll 131 live births following direct (maternal) exposure to ribavirin and 131 live births following indirect (male) exposures.<jats:bold>RESULTS<\/jats:bold>: After more than five years of operation, the Registry has enrolled 49 live births with direct exposure and 69 live births following indirect exposure. Six outcomes with birth defects have been reported. All were among live born infants: torticollis (2), hypospadias (1), polydactyly and a neonatal tooth (1), glucose\u20106\u2010phosphate dehydrogenase deficiency (1), ventricular septal defect and cyst of 4th ventricle of the brain (1). Three received direct exposures ([6.1% (95% CI: 1.2, 16.9)], three were exposed indirectly [4.3% (95% CI: 0.9, 12.2)].<jats:bold>CONCLUSIONS<\/jats:bold>: Although current enrollment is far short of the required sample size, preliminary findings have not detected a signal indicating human teratogenicity for ribavirin. However, findings must be interpreted with caution concerning direct or indirect prenatal ribavirin exposures. Birth Defects Research (Part A), 2010. \u00a9 2010 Wiley\u2010Liss, Inc.<\/jats:p>","DOI":"10.1002\/bdra.20682","type":"journal-article","created":{"date-parts":[[2010,6,17]],"date-time":"2010-06-17T14:52:18Z","timestamp":1276786338000},"page":"551-559","source":"Crossref","is-referenced-by-count":63,"title":["The Ribavirin Pregnancy Registry: Findings after 5 years of enrollment, 2003\u20132009"],"prefix":"10.1002","volume":"88","author":[{"given":"Susan S.","family":"Roberts","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith K.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen L.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael F.","family":"Greene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willis C.","family":"Maddrey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian T.","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Spiegel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,7,13]]},"reference":[{"key":"e_1_2_5_2_1","volume-title":"Antiretroviral Pregnancy Registry International Interim Report for 1 January 1989 through 31 January 2009","author":"Antiretroviral Pregnancy Registry Steering Committee","year":"2009"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-144-10-200605160-00004"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.510310332"},{"key":"e_1_2_5_5_1","unstructured":"Be In Charge.2010. Schering Corporation Kenilworth NJ. Available at:http:\/\/www.beincharge.com\/bic\/application. Accessed February 23 2010."},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10105"},{"key":"e_1_2_5_7_1","volume-title":"Metropolitan Atlanta Congenital Defects Program. Surveillance procedure manual and guide to computerized anomaly record","author":"Centers for Disease Control and Prevention (CDC)","year":"1998"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10111"},{"issue":"1","key":"e_1_2_5_9_1","first-page":"S13","article-title":"Impact of Prenatal Testing on Birth Defect Prevalence in Pregnancy Exposure Registries","volume":"17","author":"Covington DL","year":"2008","journal-title":"Pharmacoepidemiol Drug Safe"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.982"},{"key":"e_1_2_5_11_1","first-page":"498","article-title":"Mechanism of Cytotoxicity of Ribavirin in the Rat Bone Marrow and Testis","volume":"46","author":"D'Souza U","year":"2002","journal-title":"Indian J Physiol Pharmacol"},{"key":"e_1_2_5_12_1","first-page":"1","article-title":"Surveillance for acute viral hepatitis \u2010 US, 2007","volume":"58","author":"Daniels D","year":"2009","journal-title":"MMWR Surveill Summ"},{"key":"e_1_2_5_13_1","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/135965350300800110","article-title":"Paternal exposure to ribavirin: pregnancy and neonatal outcome","volume":"8","author":"De Santis M","year":"2003","journal-title":"Antivir Ther"},{"key":"e_1_2_5_14_1","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1998.8371"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420170117"},{"key":"e_1_2_5_16_1","volume-title":"Guidance for industry: establishing pregnancy exposure registries","author":"Food and Drug Administration (FDA)","year":"2002"},{"key":"e_1_2_5_17_1","first-page":"125","volume-title":"Registries for evaluating patient outcomes: a user's guide","author":"Gliklich RE","year":"2007"},{"issue":"1","key":"e_1_2_5_18_1","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue P","year":"1999","journal-title":"Semin Liver Dis"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03997.x"},{"key":"e_1_2_5_20_1","unstructured":"HoferH DonnererJ SatorK et al.2007. Morphological analysis and assessment of HCV\u2010RNA and ribavirin concentration in seminal fluid of chronic hepatitis C patients undergoing antiviral combination therapy. AASLD 2007 Abstract no. 263 2007. Available at:http:\/\/www.hcvadvocate.org\/news\/reports\/AASLD_2007\/Abstracts\/Saturday%20Posters.htm. Accessed October 14 2009."},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-9926(199912)60:6<356::AID-TERA8>3.0.CO;2-B"},{"key":"e_1_2_5_22_1","volume-title":"IRB Review of Research. Code of Federal Regulations","author":"Institutional Review Boards","year":"2009"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.401547"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0041-008X(80)90252-5"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2007.07.002"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1439-0272.1998.tb01381.x"},{"issue":"1","key":"e_1_2_5_27_1","first-page":"67","article-title":"Safety of combination interferon alfa\u20102b\/ribavirin therapy in chronic hepatitis C\u2010relapsed and treatment\u2010naive patients","volume":"19","author":"Maddrey W","year":"1999","journal-title":"Semin Liver Dis"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2001.03996.x"},{"key":"e_1_2_5_29_1","series-title":"Management of Hepatitis C: Consensus Development Conference Statement","first-page":"1","author":"National Institutes of Health (NIH)","year":"2002"},{"key":"e_1_2_5_30_1","first-page":"97","article-title":"Effect of ribavirin on epididymal sperm count in rat","volume":"46","author":"Narayana K","year":"2002","journal-title":"Indian J Physiol Pharmacol"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1383-5718(01)00308-4"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.fertnstert.2008.07.1755"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdra.10020"},{"key":"e_1_2_5_34_1","first-page":"750","volume-title":"Current diagnosis and treatment: pediatrics","author":"Polousky JD","year":"2009"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.reprotox.2005.06.005"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.4103\/0253-7613.15108"},{"key":"e_1_2_5_37_1","volume-title":"Rebetol","author":"Schering Corporation","year":"2009"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/SGA.0b013e31818eb70d"},{"key":"e_1_2_5_39_1","unstructured":"RobertsSSandthe Scientific Advisory Board of the Ribavirin Pregnancy Registry.2005.The Ribavirin Pregnancy Registry is established. Poster presented at the CDC's National Viral Hepatitis Prevention Conference Washington DC December 5\u20139."},{"issue":"1","key":"e_1_2_5_40_1","first-page":"S12","article-title":"Prenatal testing prior to enrollment in pregnancy exposure registries","volume":"15","author":"Roberts S","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"e_1_2_5_41_1","first-page":"S77","article-title":"Paternal exposures and birth defects: overlooked or unnecessary?","volume":"18","author":"Roberts SS","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"e_1_2_5_42_1","volume-title":"Copegus","author":"Roche Laboratories","year":"2009"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.726"},{"key":"e_1_2_5_44_1","first-page":"1","article-title":"Centers for Disease Control and Prevention (CDC). Abortion surveillance\u2013US, 2004","volume":"56","author":"Strauss LT","year":"2007","journal-title":"MMWR Surveill Summ"},{"key":"e_1_2_5_45_1","doi-asserted-by":"crossref","first-page":"313","DOI":"10.7883\/yoken.JJID.2005.313","article-title":"Genotoxic effect of ribavirin in patients with Crimean\u2010Congo hemorrhagic fever","volume":"58","author":"Tatar A","year":"2005","journal-title":"Jpn J Infect Dis"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/pd.1948"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/humrep\/14.12.3023"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2006.02704.x"}],"container-title":["Birth Defects Research Part A: Clinical and Molecular Teratology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdra.20682","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdra.20682","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T17:26:56Z","timestamp":1711560416000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdra.20682"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,7]]},"references-count":47,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2010,7]]}},"alternative-id":["10.1002\/bdra.20682"],"URL":"https:\/\/doi.org\/10.1002\/bdra.20682","archive":["Portico"],"relation":{},"ISSN":["1542-0752","1542-0760"],"issn-type":[{"value":"1542-0752","type":"print"},{"value":"1542-0760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,7]]}}}